KD6-287

KD6-287 is an inactivated, Vero cell-derived Japanese encephalitis vaccine developed by KM Biologics. It is a monovalent vaccine containing the inactivated Beijing-1 strain of the Japanese encephalitis virus (JEV). KD6-287 is currently in Phase III clinical development in Japan, where it is being evaluated for immunogenicity and safety in pediatric populations, including healthy infants and children. The vaccine is intended to prevent Japanese encephalitis, a serious mosquito-borne viral infection of the brain. It is typically administered as a primary series of two doses followed by a booster dose. KD6-287 is a liquid formulation, distinguishing it from the company's existing freeze-dried Japanese encephalitis vaccine (KD-287/ENCEVAC).